S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)

Shore Capital Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Shore Capital. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Shore Capital.

MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyDateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
GSK
GlaxoSmithKline
2/12/2020Downgraded byShore CapitalHold -> SellLow
GSK
GlaxoSmithKline
3/8/2019Downgraded byShore CapitalBuy -> HoldLow
GSK
GlaxoSmithKline
7/27/2018Upgraded byShore CapitalHold -> BuyLow
AZN
AstraZeneca
11/10/2016Reiterated byShore CapitalHoldN/A
JHS
John Hancock Income Securities Trust
10/10/2016Reiterated byShore CapitalBuyN/A
AZN
AstraZeneca
10/8/2016Reiterated byShore CapitalHoldN/A
NWG
NatWest Group
9/28/2016Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
9/28/2016Reiterated byShore CapitalHoldN/A
JHS
John Hancock Income Securities Trust
9/14/2016Reiterated byShore CapitalBuyN/A
AZN
AstraZeneca
9/3/2016Reiterated byShore CapitalHoldN/A
GSK
GlaxoSmithKline
8/17/2016Reiterated byShore CapitalHoldN/A
GSK
GlaxoSmithKline
8/11/2016Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
8/10/2016Reiterated byShore CapitalHoldN/A
QCLN
First Trust NASDAQ Clean Edge Green Energy Index Fund
8/6/2016Reiterated byShore CapitalBuyN/A
BCS
Barclays
8/1/2016Reiterated byShore CapitalBuyN/A
PSO
Pearson
7/31/2016Reiterated byShore CapitalHoldN/A
GSK
GlaxoSmithKline
7/27/2016Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
7/27/2016Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
7/20/2016Reiterated byShore CapitalHoldN/A
JHS
John Hancock Income Securities Trust
7/19/2016Reiterated byShore CapitalBuyN/A
GSK
GlaxoSmithKline
7/19/2016Reiterated byShore CapitalHoldN/A
QCLN
First Trust NASDAQ Clean Edge Green Energy Index Fund
6/29/2016Reiterated byShore CapitalBuyN/A
PROV
Provident Financial
6/25/2016Reiterated byShore CapitalHoldN/A
PSO
Pearson
6/21/2016Reiterated byShore CapitalHoldN/A
GSK
GlaxoSmithKline
6/21/2016Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
6/14/2016Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
5/17/2016Reiterated byShore CapitalHoldN/A
BCS
Barclays
3/1/2016Reiterated byShore CapitalHoldN/A
PROV
Provident Financial
2/23/2016Reiterated byShore CapitalHoldN/A
HSBC
HSBC
2/23/2016Reiterated byShore CapitalSellN/A
NWG
NatWest Group
1/27/2016Reiterated byShore CapitalBuyN/A
UL
Unilever
1/19/2016Reiterated byShore CapitalBuyN/A
PROV
Provident Financial
1/13/2016Reiterated byShore CapitalHoldN/A
DEO
Diageo
11/12/2015Reiterated byShore CapitalHoldN/A
LYG
Lloyds Banking Group
10/30/2015Upgraded byShore CapitalBuyN/A
BCS
Barclays
10/28/2015Reiterated byShore CapitalHoldN/A
DEO
Diageo
9/23/2015Reiterated byShore CapitalHoldN/A
DEO
Diageo
9/17/2015Reiterated byShore CapitalHoldN/A
BCS
Barclays
8/13/2015Downgraded byShore CapitalHoldN/A
NWG
NatWest Group
7/29/2015Reiterated byShore CapitalHoldN/A
DEO
Diageo
7/3/2015Reiterated byShore CapitalHoldN/A
DEO
Diageo
6/8/2015Reiterated byShore CapitalHoldN/A
AZN
AstraZeneca
4/13/2015Reiterated byShore CapitalBuyN/A
GSK
GlaxoSmithKline
3/20/2015Reiterated byShore CapitalBuyN/A
AZN
AstraZeneca
3/16/2015Reiterated byShore CapitalBuyN/A
PUK
Prudential
3/10/2015Reiterated byShore CapitalBuyN/A
BCS
Barclays
3/3/2015Reiterated byShore CapitalBuyN/A
GSK
GlaxoSmithKline
2/6/2015Reiterated byShore CapitalBuyN/A
AZN
AstraZeneca
1/27/2015Reiterated byShore CapitalBuyN/A
UL
Unilever
1/20/2015Reiterated byShore CapitalBuyN/A
DEO
Diageo
12/18/2014Reiterated byShore CapitalHoldN/A
LYG
Lloyds Banking Group
12/16/2014Reiterated byShore CapitalHoldN/A
HSBC
HSBC
12/16/2014Reiterated byShore CapitalHoldN/A
BCS
Barclays
12/16/2014Reiterated byShore CapitalBuyN/A
CCL
Carnival Co. &
9/12/2014Upgraded byShore CapitalHold -> BuyN/A
GSK
GlaxoSmithKline
4/28/2014Reiterated byShore CapitalBuyN/A
ABM
ABM Industries
10/2/2013Reiterated byShore CapitalSell -> SellN/A
HSBC
HSBC
7/3/2013Reiterated byShore CapitalBuyN/A
BCS
Barclays
7/3/2013Reiterated byShore CapitalBuyN/A
BCS
Barclays
6/13/2013Reiterated byShore CapitalBuyN/A
ABM
ABM Industries
5/28/2013Reiterated byShore CapitalSellN/A
BCS
Barclays
5/23/2013Reiterated byShore CapitalBuyN/A
UL
Unilever
4/26/2013Reiterated byShore CapitalBuyN/A
DEO
Diageo
4/26/2013Reiterated byShore CapitalBuyN/A
ALB
Albemarle
4/22/2013Reiterated byShore CapitalSellN/A
ABM
ABM Industries
4/22/2013Reiterated byShore CapitalSell -> SellN/A
IHG
InterContinental Hotels Group
3/28/2013Reiterated byShore CapitalSellN/A
BWXT
BWX Technologies
3/26/2013Reiterated byShore CapitalHoldN/A
DEO
Diageo
3/22/2013Reiterated byShore CapitalBuyN/A
HSBC
HSBC
3/19/2013Upgraded byShore CapitalBuyN/A

MarketBeat Community Rating for Shore Capital

Community Ranking:  2.8 out of 5 (star star half star)
Outperform Votes:  17,742 (Vote Outperform)
Underperform Votes:  14,125 (Vote Underperform)
Total Votes:  31,867
MarketBeat's community ratings are surveys of what our community members think about Shore Capital and other research firms. Vote "Outperform" if you believe Shore Capital's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Shore Capital's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.